Dr Luca Sangiorgi helds a Medical degree from the University of Bologna, a PhD in Clinical Genetics at “La Sapienza” University of Rome and a Master Degree in Research Promotion and Governance in Hospital Trusts and Local Health Units at the University of Modena and Reggio Emilia.
He has been Visiting Scientist at the Molecular Oncology Section, Paediatric Branch of the National Cancer Institute in Maryland (USA).
He is coordinator of the Rizzoli Rare Disease Center and responsible of four National Registers of Rare Disease (Multiple Hereditary Exostoses, Osteogenesis Imperfecta, Ehrler Danlos and Ollier Disease). He also coordinates the Emilia Romagna Region Hub and Spoke Network on Rare Bone Disorders.
Italian representative in the Assembly of Member States (AoM) of BBMRI (Biobanking and Biomolecular Resources Research Infrastructure) since 2013, he is currently acting as Chair of the AoM and Coordinator of the BBMRI Rare Disease Interest Group.
Since December 2014 he is acting as Alternate of the Representative of Italian Government for the Committee for Advanced Therapies (CAT) of the European Medicine Agency (EMA).
Since March 2017 he is the coordinator of BOND ERN that includes 38 Centres of Excellence for the treatment of Rare Bone Disorders in 10 EU Member States.
As member of many different medical and scientific societies, he has been appointed President of Connective Tissue Oncology Society and International Skeletal Dysplasia Society.